What Is One of the Best Pharmaceutical Stocks to Buy Right Now?

Group 1 - AbbVie is recognized for its strong product lineup, robust pipeline, and consistent dividend payments, making it an attractive investment opportunity [1][6] - The company has developed at least 12 blockbuster drugs, including Skyrizi and Botox, generating nearly $47 billion in net revenue for full-year 2024 [2] - AbbVie reported a nearly 7% year-over-year increase in net revenue to $15.4 billion, with adjusted net income per share rising by 12% to $2.97 [3] Group 2 - AbbVie has demonstrated significant free cash flow over the past five years, ranging from approximately $16.8 billion to $24.2 billion, indicating strong financial health [4] - The company is classified as a Dividend King, having increased its dividend for at least 50 consecutive years, with a current quarterly payout of $1.64 per share, yielding just under 3% [5] - The combination of a solid product lineup and high dividend payout is rare in the pharmaceutical industry, positioning AbbVie as a unique investment candidate [6]